Loading...
Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab
The epidermal growth factor receptor (EGFR) is an ubiquitously expressed receptor tyrosine kinase (RTK) and is recognized as a key mediator of tumorigenesis in many human tumors. Currently there are five EGFR inhibitors used in oncology, two monoclonal antibodies (panitumumab and cetuximab) and thre...
Na minha lista:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Landes Bioscience
2011
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3219082/ https://ncbi.nlm.nih.gov/pubmed/21725209 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.12.5.16394 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|